Cited 0 times in
Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
|dc.description.abstract||BACKGROUND: Despite advances in palliative chemotherapy, patients with advanced non-small cell lung cancer (NSCLC) eventually experience disease progression during or after completion of first-line chemotherapy, which requires salvage therapy. Second- or third-line therapy in selected patients is recommended in the current guidelines. Although fourth-line therapy is often performed in daily practice in some countries, there are few reports about the clinical benefits of fourth-line therapy.
PATIENTS AND METHODS: A retrospective review was conducted on 383 patients who underwent at least first-line palliative chemotherapy for advanced NSCLC (stage IV or stage IIIB/recurrent disease unsuitable for definitive local therapy). Overall survival (OS) and clinicopathological characteristics were analyzed according to the lines of chemotherapy as well as for all study patients.
RESULTS: The median OS for all patients after the initiation of first-line therapy was 11 months. The median OS for patients who received fourth- or further-line therapy (77 patients) was longer than that of patients who received third- or lesser-line therapy (27 versus 9 months, p<0.0001). In multivariate analysis, fourth- or further-line therapy was independently associated with favorable OS (hazard ratio: 0.44, 95% confidence interval: 0.34-0.57, p<0.0001) along with recurrent disease, female, age <70 years, and ECOG performance status (PS) 0 or 1. Median OS after the start of fourth-line therapy was 9 months. Good PS (ECOG PS 0, 1) at the initiation of fourth-line therapy (10 versus 2 months, p<0.0001) and disease control (10 versus 7 months, p=0.011) after first-line therapy were associated with favorable OS in univariate analysis, while poor PS (ECOG PS ≥2) was an independent prognostic factor for poor outcome (p<0.0001).
CONCLUSION: The present study suggests that advanced NSCLC patients with good PS after progression from third-line therapy could be considered as reasonable candidates for fourth-line therapy in clinical practice.
|dc.subject.MESH||Aged, 80 andover||-|
|dc.subject.MESH||Antineoplastic Combined Chemotherapy Protocols/therapeutic use||-|
|dc.subject.MESH||Carcinoma, Non-Small-Cell Lung/drug therapy||-|
|dc.subject.MESH||Carcinoma, Non-Small-Cell Lung/mortality||-|
|dc.subject.MESH||Carcinoma, Non-Small-Cell Lung/pathology||-|
|dc.subject.MESH||Lung Neoplasms/drug therapy||-|
|dc.title||Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?||-|
|dc.citation.title||Lung cancer (Amsterdam, Netherlands)||-|
|dc.identifier.bibliographicCitation||Lung cancer (Amsterdam, Netherlands), 87(2). : 155-161, 2015||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.